Abstract
Aims: To use linked routinely-collected health data to estimate diabetes prevalence and incidence in an Australian cohort of adults aged ≥45 years, and examine risk factors associated with incident disease. Research design and methods: The EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (EXTEND45) Study is a linked data study that combines baseline questionnaire responses from the population-based 45 and Up Study (2006–2009, n = 267,153) with multiple routinely-collected health databases up to December 2014. Among participants with ≥1 linked result for any laboratory test, diabetes status was determined from multiple data sources according to standard biochemical criteria, use of glucose-lowering medication or self-report, and the prevalence and incidence rate calculated. Independent risk factors of incident diabetes were examined using multivariable Cox regression. Results: Among 152,169 45 and Up Study participants with ≥1 linked laboratory result in the EXTEND45 database (mean age 63.0 years; 54.9% female), diabetes prevalence was 10.8% (95% confidence interval [CI] 10.6%–10.9%). Incident disease in those without diabetes at baseline (n = 135,810; mean age 62.5 years; 56.1% female) was 10.0 per 1,000 person-years (95% CI 9.8–10.2). In all age groups, diabetes incidence was lower in women compared to men, an association that persisted in the fully adjusted analyses. Other independent risk factors of diabetes were older age, being born outside of Australia (with the highest rate of 19.2 per 1,000 person-years observed in people born in South and Central Asia), lower education status, lower annual household income, residence in a major city, family history of diabetes, personal history of cardiovascular disease or hypertension, higher body mass index, smoking and long sleeping hours. Conclusions: Our study represents an efficient approach to assessing diabetes frequency and its risk factors in the community. The infrastructure provided by the EXTEND45 Study will be useful for diabetes surveillance and examining other important clinical and epidemiological questions.
| Original language | English |
|---|---|
| Article number | 100240 |
| Number of pages | 9 |
| Journal | Journal of Clinical and Translational Endocrinology |
| Volume | 22 |
| DOIs | |
| Publication status | Published - Dec 2020 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Administrative data
- Big data
- Diabetes MELLITUS
- Incidence
- Prevalence
- Risk factors
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Clinical and Translational Endocrinology, Vol. 22, 100240, 12.2020.
Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Prevalence, incidence and risk factors of diabetes in Australian adults aged ≥45 years
T2 - A cohort study using linked routinely-collected data
AU - Zhang, Hongmei
AU - Rogers, Kris
AU - Sukkar, Louisa
AU - Jun, Min
AU - Kang, Amy
AU - Young, Tamara
AU - Campain, Anna
AU - Cass, Alan
AU - Chow, Clara K.
AU - Comino, Elizabeth
AU - Foote, Celine
AU - Gallagher, Martin
AU - Knight, John
AU - Liu, Bette
AU - Lung, Thomas
AU - McNamara, Martin
AU - Peiris, David
AU - Pollock, Carol
AU - Sullivan, David
AU - Wong, Germaine
AU - Zoungas, Sophia
AU - Jardine, Meg
AU - Hockham, Carinna
N1 - Funding Information: This research was completed using data collected through the 45 and Up Study ( www.saxinstitute.org.au ). The 45 and Up Study is managed by the Sax Institute in collaboration with major partner Cancer Council NSW; and partners: the National Heart Foundation of Australia (NSW Division); NSW Ministry of Health; NSW Government Family & Community Services – Ageing, Carers and the Disability Council NSW; and the Australian Red Cross Blood Service. We thank the many thousands of people participating in the 45 and Up Study, without whose ongoing contributions our research would not be possible. In addition, we thank Services Australia for their supply of MBS and PBS data; NSW Ministry of Health for providing data held in the NSW Central Cancer Registry, NSW Admitted Patient Data Collection and Registry of Births, Deaths and Marriages; and the ANZDATA Registry and private pathology companies who have contributed their data to this study. The NSW Centre for Health Record Linkage (CHeReL) and the Sax Institute performed the data linkage. Funding Information: The EXTEND45 Study is in part funded through peer-reviewed, unconditional grants, including an NSW Cardiovascular Research Network Development Project Grant from the National Heart Foundation of Australia (award no. 100720 ), a seeding GENESIS grant supported by Roche Products Pty Ltd. (grant no. FR-MIR-0095 ), and a Rebecca L Cooper Grant (grant no. REB002 ). In addition, the study was supported in part by unconditional research grants from Eli Lilly (Australia) Pty Ltd. (grant no. PO4100294024 ), Merck Sharp & Dohme (Australia) Pty Ltd. (grant no. MSD_EXTEND45 ), and Amgen (Australia) Pty Ltd. (grant no. Amgen01 ). None of the funding bodies were involved in the design of the study and analysis and interpretation of the study. The study sponsors were not involved in the content development of the EXTEND45 Study. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Eli Lilly (Australia) Pty Ltd, Merck Sharp & Dohme (Australia) Pty Ltd, or Amgen (Australia) Pty Ltd. Funding Information: This research was completed using data collected through the 45 and Up Study (www.saxinstitute.org.au). The 45 and Up Study is managed by the Sax Institute in collaboration with major partner Cancer Council NSW; and partners: the National Heart Foundation of Australia (NSW Division); NSW Ministry of Health; NSW Government Family & Community Services ? Ageing, Carers and the Disability Council NSW; and the Australian Red Cross Blood Service. We thank the many thousands of people participating in the 45 and Up Study, without whose ongoing contributions our research would not be possible. In addition, we thank Services Australia for their supply of MBS and PBS data; NSW Ministry of Health for providing data held in the NSW Central Cancer Registry, NSW Admitted Patient Data Collection and Registry of Births, Deaths and Marriages; and the ANZDATA Registry and private pathology companies who have contributed their data to this study. The NSW Centre for Health Record Linkage (CHeReL) and the Sax Institute performed the data linkage. H.Z. contributed to the design, interpretation of the data and writing of the manuscript. K.R. contributed to the design, statistical analysis, interpretation of the data and critical review of the manuscript. L.S. M.Ju. A.K. T.Y. A.Cam. all contributed to the design and critical review of the manuscript. A.Cas. C.K.C. E.C. M.G. J.K. B.L. T.L. M.M. D.P. C.P. D.S. G.W. S.Z. all contributed to the critical review of the manuscript. C.F. contributed to the acquisition of data and critical review of the manuscript. M.Ja. contributed to the design, acquisition of data, interpretation of the data, supervision, writing and critical review of the manuscript. CH contributed to the interpretation of the data, supervision and management of the research, writing and critical review of the manuscript. All authors affirm that authorship is merited based on the International Committee of Medical Journal Editors authorship criteria. K.R. M.Ja. and C.H. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The EXTEND45 Study is in part funded through peer-reviewed, unconditional grants, including an NSW Cardiovascular Research Network Development Project Grant from the National Heart Foundation of Australia (award no. 100720), a seeding GENESIS grant supported by Roche Products Pty Ltd. (grant no. FR-MIR-0095), and a Rebecca L Cooper Grant (grant no. REB002). In addition, the study was supported in part by unconditional research grants from Eli Lilly (Australia) Pty Ltd. (grant no. PO4100294024), Merck Sharp & Dohme (Australia) Pty Ltd. (grant no. MSD_EXTEND45), and Amgen (Australia) Pty Ltd. (grant no. Amgen01). None of the funding bodies were involved in the design of the study and analysis and interpretation of the study. The study sponsors were not involved in the content development of the EXTEND45 Study. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Eli Lilly (Australia) Pty Ltd, Merck Sharp & Dohme (Australia) Pty Ltd, or Amgen (Australia) Pty Ltd. MJu has received unrestricted grant support from VentureWise (a wholly own commercial subsidiary of NPS MedicineWise) to conduct a commissioned project funded by AstraZeneca. CKC is the Asia Pacific Scientific Leader for Vertis, has received sponsorship from Merck Sharp & Dohme and has been a speaker for Bayer. MG has received honoraria from Shire Pharmaceuticals and Amgen Pty Ltd. CP is the current Chair of: Kidney Health Australia, NSW Bureau Health Information and the NSW Cardiovascular Research Network; is a member of the International Advisory Board for AstraZeneca; is a member of Local Advisory Boards for Vifor, Merck Sharpe & Dohm, Boehringer Ingelheim and Otsuka; serves on the Scientific Advisory Board of Pharmaxis; has received travel and accommodation support from Amgen, AstraZeneca and Roche; and has received speaker support from Amgen, AstraZeneca, Novartis and Vifor. DS has received research support from Amgen, Sanofi, Pfizer, Regeneron, Amrin, AstraZeneca and Novartis and provided consultancy services to Amgen, Arrowhead Pharmaceuticals and Sanofi. SZ has participated in the Advisory Board, expert committees, or educational meetings for Boehringer Ingelheim, Eli Lilly, Sanofi, Servier, AstraZeneca, Novo Nordisk, and Merck Sharp & Dohme on behalf of Monash University, with no direct financial compensation. MJa is supported by a Medical Research Future Fund Next Generation Clinical Researchers Program Career Development Fellowship; is responsible for research projects that have received unrestricted funding from Gambro, Baxter, CSL Behring, Amgen, Eli Lilly, and Merck; has served on advisory boards sponsored by Akebia, Baxter, Boehringer Ingelheim and Vifor, spoken at scientific meetings sponsored by Janssen, Amgen and Roche; with any consultancy, honoraria or travel support paid to her institution. HZ, KR, LS, AK, TY, ACam, ACas, EC, CF, JK, BL, TL, MM, DP, GW and CH have no competing interests to declare. Funding Information: MJu has received unrestricted grant support from VentureWise (a wholly own commercial subsidiary of NPS MedicineWise) to conduct a commissioned project funded by AstraZeneca. CKC is the Asia Pacific Scientific Leader for Vertis, has received sponsorship from Merck Sharp & Dohme and has been a speaker for Bayer. MG has received honoraria from Shire Pharmaceuticals and Amgen Pty Ltd. CP is the current Chair of: Kidney Health Australia, NSW Bureau Health Information and the NSW Cardiovascular Research Network; is a member of the International Advisory Board for AstraZeneca; is a member of Local Advisory Boards for Vifor, Merck Sharpe & Dohm, Boehringer Ingelheim and Otsuka; serves on the Scientific Advisory Board of Pharmaxis; has received travel and accommodation support from Amgen, AstraZeneca and Roche; and has received speaker support from Amgen, AstraZeneca, Novartis and Vifor. DS has received research support from Amgen, Sanofi, Pfizer, Regeneron, Amrin, AstraZeneca and Novartis and provided consultancy services to Amgen, Arrowhead Pharmaceuticals and Sanofi. SZ has participated in the Advisory Board, expert committees, or educational meetings for Boehringer Ingelheim, Eli Lilly, Sanofi, Servier, AstraZeneca, Novo Nordisk, and Merck Sharp & Dohme on behalf of Monash University, with no direct financial compensation. MJa is supported by a Medical Research Future Fund Next Generation Clinical Researchers Program Career Development Fellowship; is responsible for research projects that have received unrestricted funding from Gambro, Baxter, CSL Behring, Amgen, Eli Lilly, and Merck; has served on advisory boards sponsored by Akebia, Baxter, Boehringer Ingelheim and Vifor, spoken at scientific meetings sponsored by Janssen, Amgen and Roche; with any consultancy, honoraria or travel support paid to her institution. HZ, KR, LS, AK, TY, ACam, ACas, EC, CF, JK, BL, TL, MM, DP, GW and CH have no competing interests to declare. Publisher Copyright: © 2020 The Authors Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2020/12
Y1 - 2020/12
N2 - Aims: To use linked routinely-collected health data to estimate diabetes prevalence and incidence in an Australian cohort of adults aged ≥45 years, and examine risk factors associated with incident disease. Research design and methods: The EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (EXTEND45) Study is a linked data study that combines baseline questionnaire responses from the population-based 45 and Up Study (2006–2009, n = 267,153) with multiple routinely-collected health databases up to December 2014. Among participants with ≥1 linked result for any laboratory test, diabetes status was determined from multiple data sources according to standard biochemical criteria, use of glucose-lowering medication or self-report, and the prevalence and incidence rate calculated. Independent risk factors of incident diabetes were examined using multivariable Cox regression. Results: Among 152,169 45 and Up Study participants with ≥1 linked laboratory result in the EXTEND45 database (mean age 63.0 years; 54.9% female), diabetes prevalence was 10.8% (95% confidence interval [CI] 10.6%–10.9%). Incident disease in those without diabetes at baseline (n = 135,810; mean age 62.5 years; 56.1% female) was 10.0 per 1,000 person-years (95% CI 9.8–10.2). In all age groups, diabetes incidence was lower in women compared to men, an association that persisted in the fully adjusted analyses. Other independent risk factors of diabetes were older age, being born outside of Australia (with the highest rate of 19.2 per 1,000 person-years observed in people born in South and Central Asia), lower education status, lower annual household income, residence in a major city, family history of diabetes, personal history of cardiovascular disease or hypertension, higher body mass index, smoking and long sleeping hours. Conclusions: Our study represents an efficient approach to assessing diabetes frequency and its risk factors in the community. The infrastructure provided by the EXTEND45 Study will be useful for diabetes surveillance and examining other important clinical and epidemiological questions.
AB - Aims: To use linked routinely-collected health data to estimate diabetes prevalence and incidence in an Australian cohort of adults aged ≥45 years, and examine risk factors associated with incident disease. Research design and methods: The EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (EXTEND45) Study is a linked data study that combines baseline questionnaire responses from the population-based 45 and Up Study (2006–2009, n = 267,153) with multiple routinely-collected health databases up to December 2014. Among participants with ≥1 linked result for any laboratory test, diabetes status was determined from multiple data sources according to standard biochemical criteria, use of glucose-lowering medication or self-report, and the prevalence and incidence rate calculated. Independent risk factors of incident diabetes were examined using multivariable Cox regression. Results: Among 152,169 45 and Up Study participants with ≥1 linked laboratory result in the EXTEND45 database (mean age 63.0 years; 54.9% female), diabetes prevalence was 10.8% (95% confidence interval [CI] 10.6%–10.9%). Incident disease in those without diabetes at baseline (n = 135,810; mean age 62.5 years; 56.1% female) was 10.0 per 1,000 person-years (95% CI 9.8–10.2). In all age groups, diabetes incidence was lower in women compared to men, an association that persisted in the fully adjusted analyses. Other independent risk factors of diabetes were older age, being born outside of Australia (with the highest rate of 19.2 per 1,000 person-years observed in people born in South and Central Asia), lower education status, lower annual household income, residence in a major city, family history of diabetes, personal history of cardiovascular disease or hypertension, higher body mass index, smoking and long sleeping hours. Conclusions: Our study represents an efficient approach to assessing diabetes frequency and its risk factors in the community. The infrastructure provided by the EXTEND45 Study will be useful for diabetes surveillance and examining other important clinical and epidemiological questions.
KW - Administrative data
KW - Big data
KW - Diabetes MELLITUS
KW - Incidence
KW - Prevalence
KW - Risk factors
UR - https://www.scopus.com/pages/publications/85096683550
U2 - 10.1016/j.jcte.2020.100240
DO - 10.1016/j.jcte.2020.100240
M3 - Article
C2 - 33294382
AN - SCOPUS:85096683550
SN - 2214-6237
VL - 22
JO - Journal of Clinical and Translational Endocrinology
JF - Journal of Clinical and Translational Endocrinology
M1 - 100240
ER -